Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance

Future Oncology, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2qOfRs7
via IFTTT